RSWM
CGTX icon

Robertson Stephens Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Robertson Stephens Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
10,000
– – ﹤0.01% 645
2026
Q1 		$7.59K Hold
10,000
– – ﹤0.01% 615
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 645
2025
Q3 		$13.5K Buy
+10,000
New +$13.6K ﹤0.01% 530

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Robertson Stephens Wealth Management's CGTX Position: Q2 2026 in Review

Robertson Stephens Wealth Management held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 10,000 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Robertson Stephens Wealth Management first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.5K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Robertson Stephens Wealth Management held 10,000 shares of Cognition Therapeutics worth $11.5K as of Q2 2026.
  • Robertson Stephens Wealth Management left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Robertson Stephens Wealth Management's portfolio in Q2 2026, its #645 holding.
  • Robertson Stephens Wealth Management first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Robertson Stephens Wealth Management's Cognition Therapeutics position peaked at $13.5K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.